Devyser Diagnostics Q4 - A robust quarter for the overlooked high-performer
2023-02-22 17:00:00
Redeye is positive to Devyser’s Q4 report as the company continues to deliver well on its key metrics and demonstrates a progress in line with its financial targets. Sales came in line, and OPEX was overall in check compared to our estimates. We lower our WACC based on a review of Redeye Quality Rating and update our fair value range accordingly.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/